0
0
Preliminary UK risk assessment of the SARS-COV-2 Omicron variant suggests high transmissibility and reduced protection among those who’ve already had the virus. Also, uncertainty on the question of vaccine effectiveness and therapies – unknown infection severity. More HERE
Modelling by University of Oxford indicates that mutations present in Omicron are highly likely to affect the binding of natural and therapeutic antibodies, and to enhance binding to human ACE2 greater than that seen in other variants to date.
The study says Delta remains the predominant variant in England accounting for approximately 99.8% of sequenced cases from 10 October to 30 November 2021
None of the cases detected so far in the UK of are known to have been hospitalized or died.
As of Dec. 3 there are 104 cases identified in the UK. Details HERE:
Link to technical briefing HERE
